Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
dc.contributor.author | Greally, Peter | |
dc.contributor.author | Whitaker, Paul | |
dc.contributor.author | Peckham, Daniel | |
dc.date.accessioned | 2012-12-07T11:43:59Z | |
dc.date.available | 2012-12-07T11:43:59Z | |
dc.date.issued | 2012-06 | |
dc.identifier.citation | Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. 2012, 28 (6):1059-67 Curr Med Res Opin | en_GB |
dc.identifier.issn | 1473-4877 | |
dc.identifier.pmid | 22401602 | |
dc.identifier.doi | 10.1185/03007995.2012.674500 | |
dc.identifier.uri | http://hdl.handle.net/10147/254896 | |
dc.description.abstract | Pseudomonas aeruginosa (Pa) is the predominant pathogen infecting the airways of patients with cystic fibrosis (CF). Initial colonization is usually transient and associated with non-mucoid strains, which can be eradicated if identified early. This strategy can prevent, or at least delay, chronic Pa infection, which eventually develops in the majority of patients by their late teens or early adulthood. This article discusses the management and latest treatment developments of Pa lung infection in patients with CF, with a focus on nebulized antibiotic therapy. | |
dc.language.iso | en | en |
dc.publisher | Current medical research and opinion | en_GB |
dc.rights | Archived with thanks to Current medical research and opinion | en_GB |
dc.subject.mesh | Administration, Inhalation | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Chronic Disease | |
dc.subject.mesh | Cystic Fibrosis | |
dc.subject.mesh | Drug Resistance, Bacterial | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Models, Biological | |
dc.subject.mesh | Pseudomonas Infections | |
dc.subject.mesh | Pseudomonas aeruginosa | |
dc.subject.mesh | Respiratory Tract Infections | |
dc.title | Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. | en_GB |
dc.type | Article | en |
dc.contributor.department | National Children's Hospital, Tallaght, Dublin, Ireland. Peter.Greally@amnch.ie | en_GB |
dc.identifier.journal | Current medical research and opinion | en_GB |
dc.description.province | Leinster | en |
html.description.abstract | Pseudomonas aeruginosa (Pa) is the predominant pathogen infecting the airways of patients with cystic fibrosis (CF). Initial colonization is usually transient and associated with non-mucoid strains, which can be eradicated if identified early. This strategy can prevent, or at least delay, chronic Pa infection, which eventually develops in the majority of patients by their late teens or early adulthood. This article discusses the management and latest treatment developments of Pa lung infection in patients with CF, with a focus on nebulized antibiotic therapy. |